

About Indivior

Who We Are

Indivior is a global specialty pharmaceutical company. Our core focus is addiction medicine. We have a 20-year legacy of clinical and basic research, treatment development, health policy and patient advocacy.

Our Vision

Our vision is that all patients around the world have access to evidence-based treatment for the chronic condition and co-occurring disorders of addiction. Our goal is to transform addiction from a global human crisis to a recognized and widely treated disease.

Our History

For more than 20 years, we have worked together with policymakers, medical societies, patient advocacy groups, healthcare providers, payers and other stakeholders to educate on the disease of addiction and advocate for patient access to opioid use disorder treatment. We approached the need to expand access to evidence-based treatment by building strong relationships with our stakeholders to increase education about the scientific nature of the disease and the value of medication-assisted treatment. We have worked to be responsible, to create a supportive environment for expanding access to treatment, and to provide education, new scientific understanding and knowledge to the treatment community.

We will continue to focus on innovative therapies and educational support to expand access to treatment for patients.

Our Patient Focus

The patient journey to treatment and recovery is complex, with many barriers, such as social stigma, access to treatment and prescribers, and difficulty adhering to treatment plans¹. Stigma, prejudice and misconceptions, often coupled with feelings of guilt and shame around addiction and treatment, prevent people from coming forward and seeking the help they need. Addiction can have a devastating personal and societal impact for the individuals, families and communities that are affected¹, and it's a global human crisis we are committed to addressing.

Our Research and Development

Indivior's core guiding principle – focus on patient needs to drive decisions – informs our research and development to advance treatment innovation in the face of the growing addiction crisis. Our treatment innovations are grounded in a deep understanding of the science of addiction and unparalleled insight into the patient journey, and we are focused on developing treatments that tackle the major challenges in addiction medicine². Our research and development mission is aimed at stable drug delivery, decreased frequency of dosing, increased treatment adherence and retention, decreased diversion and misuse, improved management of overdose, and treatments for the co-occurring disorders of addiction². The Company's recent significant investment in new state-of-the-art **research and development centers in Hull, U.K. and Fort Collins, Colorado, U.S.**, further advances our endeavor to improve patient lives by pioneering new therapies, opening access to rescue medications, treating co-occurring mental health disorders and addressing unmet medical needs in the treatment of alcohol use disorders.

Corporate Profile

Global Headquarters: Richmond, Virginia, United States

Regional Offices: Slough, United Kingdom; Ontario, Canada; Mannheim, Germany; Milan, Italy; Massy, France; Sydney, Australia; Beijing, China

R&D Centers: Fort Collins, United States; Hull, United Kingdom




Our Team

1,000+ people worldwide

Our Leadership

Our Board of Directors offers a broad range of skills and backgrounds; including pharma industry, finance and research. Our Executive Committee includes management and finance expertise, in addition to experience in addiction medicine and mental health. More information on our leadership can be found at www.indivior.com.

A diverse board



London-listed

LON: INDV

Website

www.indivior.com

Our Products

Buprenorphine medication-assisted treatment, or BMAT, is a proven, effective treatment³, and we are the market leader in opioid addiction treatment. Information on our available products can be found here: [Products](#).

Our Pipeline

We have a pipeline of investigational products for the chronic relapsing conditions and related co-occurring disorders of addiction and related mental health disorders. Our pipeline strategy is designed to address unmet needs – to improve patient outcomes, minimize side effects, encourage adherence and reduce misuse and diversion. Through our addiction science, we strive to open new vistas of understanding, novel approaches to treatment and new methodologies to support measurement of clinical response².


Expanding the range of treatment options for Opioid Use Disorder



Addressing unmet needs in Central Nervous System (CNS) Disorders



Opening access to rescue medications



Addressing unmet needs in the treatment of Alcohol Use Disorders



To learn more about who we are, please visit www.indivior.com.

¹ U.S. Department of Health and Human Services (HHS), Office of the Surgeon General, Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health. Washington, DC: HHS, November 2016.

² Heidbreder, C. (2017, November). Driving innovation in addiction medicine. Biopharma Dealmakers. <https://biopharmadealmakers.nature.com/users/69929-indivior>.

³ Nasser, A. F., C. Heidbreder, R. Gomeni, P. J. Fudala, B. Zheng and M. K. Greenwald (2014). "A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence." Clin Pharmacokinet 53(9): 813-824.